Two‐Year Clinical Outcomes After Large Coronary Stent (4.0 mm) Placement: Comparison of Bare‐Metal Stent Versus Drug‐Eluting Stent

The absolute benefit of drug‐eluting stents (DES) in low‐risk patients and lesions is not well established.

[1]  S. Shin,et al.  Bare-metal stents versus drug-eluting stents in large (≥3.5mm) single coronary artery: angiographic and clinical outcomes at 6 months. , 2009, Journal of cardiology.

[2]  C. Reid,et al.  Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry. , 2008, International journal of cardiology.

[3]  M. Pfisterer,et al.  Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. , 2008, European heart journal.

[4]  M. Pfisterer,et al.  Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). , 2007, European heart journal.

[5]  R. Costa,et al.  Drug-eluting stents vs bare metal stents for the treatment of large coronary vessels. , 2007, American heart journal.

[6]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[7]  K. Kent,et al.  Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (> or =3.5 mm) coronary arteries. , 2007, The American journal of cardiology.

[8]  Patrick Whitlow,et al.  Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[9]  B. Yan,et al.  Double jeopardy: balance between bleeding and stent thrombosis with prolonged dual antiplatelet therapy after drug-eluting stent implantation. , 2006, Cardiovascular revascularization medicine : including molecular interventions.

[10]  Gregg W Stone,et al.  Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. , 2005, JAMA.

[11]  A. Santarelli,et al.  Comparison of effectiveness of sirolimus-eluting stents versus bare metal stents for percutaneous coronary intervention in patients at high risk for coronary restenosis or clinical adverse events. , 2005, The American journal of cardiology.

[12]  G. Stone,et al.  One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV Trial , 2004, Circulation.

[13]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[14]  D. Baim,et al.  Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. , 2002, Journal of the American College of Cardiology.

[15]  Antonio Colombo,et al.  Mechanism of Late In-Stent Restenosis After Implantation of a Paclitaxel Derivate–Eluting Polymer Stent System in Humans , 2002, Circulation.

[16]  M. Hadamitzky,et al.  Vessel size and long-term outcome after coronary stent placement. , 1998, Circulation.

[17]  P. Serruys,et al.  Influence of Coronary Vessel Size on Renarrowing Process and Late Angiographic Outcome After Successful Balloon Angioplast , 1994, Circulation.

[18]  P. Agostoni,et al.  Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). , 2007, European heart journal.

[19]  Ousa,et al.  A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .

[20]  Filippo Aureli,et al.  Published online in Wiley Online Library , 2022 .